Teva Pharmaceutical says rival generic drugmaker Mylan is engaging in a “desperate attempt” to keep its board and shareholders from considering Teva’s $40 billion-plus takeover offer. The claim, ...

June 13 (Reuters) - Mylan Nv: * Mylan's letter to shareholders dated june 12 says Teva’s expression of interest was simply not right for Mylan and its stakeholders * Mylan - despite Mylan’s leadership ...

Mylan has rejected Teva’s unsolicited bid. Robert J. Coury, Mylan’s executive chairman, said Teva’s roughly $40 billion offer grossly undervalues the company and “would require Mylan’s shareholders to ...

Mylan’s biggest shareholder is backing the generic drugmaker’s plan to remain a stand-alone company as it fights a takeover bid from larger rival Teva Pharmaceutical. Abbott Laboratories also says it ...

Israel's Teva Pharmaceutical Industries ($TEVA) is reported to be considering a $34 billion takeover of British-based Mylan ($MYL). But if it indeed is, the takeover ...

Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening. According ...